| Literature DB >> 24957413 |
Felix S Lichtenegger1, Robin Lorenz2, Katharina Gellhaus3, Wolfgang Hiddemann4, Barbara Beck2, Marion Subklewe5.
Abstract
Cyclic cytotoxic maintenance therapy can be applied to patients with AML in post-remission. We studied the immune status of AML patients in complete remission and the effect of maintenance therapy on different immune cell populations. Patients in complete remission had reduced NK, TH and Treg counts and a reduced NK activation capacity. In the course of cytotoxic maintenance therapy, NK counts further declined, while TH and Treg cells increased, with lower proliferative potential of TH cells. We conclude that immunotherapeutic approaches in post-remission have to consider reduced NK cell function and further impairment of cellular immune responses during cytotoxic therapy.Entities:
Keywords: Acute myeloid leukemia; Cytotoxic therapy; Immunomonitoring; Maintenance therapy; NK cell; T regulatory cell
Mesh:
Year: 2014 PMID: 24957413 DOI: 10.1016/j.leukres.2014.05.014
Source DB: PubMed Journal: Leuk Res ISSN: 0145-2126 Impact factor: 3.156